Informative censoring occurs when progression-free survival is the primary end point of a randomized clinical trial and unequal patient dropout is observed between treatment arms owing to poorer tolerance of experimental treatment. Herein we discuss how informative censoring in the experimental arm before criteria for disease progression are met causes bias towards a positive result.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial
British Journal of Cancer Open Access 25 April 2024
-
Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer
Scientific Reports Open Access 07 February 2024
-
Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts
Therapeutic Innovation & Regulatory Science Open Access 07 October 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ranganathan, P. & Pramesh, C. S. Censoring in survival analysis: potential for bias. Perspect. Clin. Res. 3, 40 (2012).
Stone, A. M. et al. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group. Eur. J. Cancer 47, 1763–1771 (2011).
Fleming, T. R., Rothmann, M. D. & Lu, H. L. Issues in using progression-free survival when evaluating oncology products. J. Clin. Oncol. 27, 2874–2880 (2009).
Shih, W. Problems in dealing with missing data and informative censoring in clinical trials. Curr. Control Trials Cardiovasc. Med. 3, 4 (2002).
Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520–529 (2012).
Piccart, M. et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann. Oncol. 25, 2357–2362 (2014).
Templeton, A. J. et al. Influence of censoring on conclusions of trials for women with metastatic breast cancer. Eur. J. Cancer 51, 721–724 (2015).
Sun, J. The Statistical Analysis of Interval-Censored Failure Time Data: Statistics for Biology and Health. (Springer, 2006).
Sparano, J. A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med. 379, 111–121 (2018).
Ethier, J.L. et al. Influence of competing risks of death on the interpretation of adjuvant endocrine therapy trials for breast cancer. Cancer Res. 79, Abstract P4-14-03 (2019).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary Information
Rights and permissions
About this article
Cite this article
Templeton, A.J., Amir, E. & Tannock, I.F. Informative censoring — a neglected cause of bias in oncology trials. Nat Rev Clin Oncol 17, 327–328 (2020). https://doi.org/10.1038/s41571-020-0368-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-020-0368-0
This article is cited by
-
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial
British Journal of Cancer (2024)
-
Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer
Scientific Reports (2024)
-
Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts
Therapeutic Innovation & Regulatory Science (2024)
-
Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology
Journal of Translational Medicine (2022)
-
Is treatment in certified cancer centers related to better survival in patients with pancreatic cancer? Evidence from a large German cohort study
BMC Cancer (2022)